Image For Activity Cover
Precision Management of Late Endocrine Effects in Cancer Survivors
Course Description

In this recorded discussion on the diagnosis and clinical management of late endocrine effects in pediatric and adult cancer survivors, hear expert perspectives on:

  • Common root causes of late endocrine effects due to cancer treatment in survivors of childhood cancer and the importance of lifelong monitoring for their development
  • Strategies to address barriers to growth hormone deficiency treatment adherence
  • Help understand the challenges of obesity and diabetes mellitus in cancer survivors

This course was a virtual live CME-certified Ancillary Symposium developed in collaboration with our partner - Clinical Care Options (CCO) to be presented at ENDO 2021. This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc. This ancillary symposium is developed through the Endocrine Society’s Special Programs Committee (SPC).

Clinical Thoughts

Click the button(s) below to open the related ClinicalThought commentaries:

Learning Objectives

Upon successful completion these educational sessions, participants should be better able to:

  • Summarize the common root causes of late endocrine effects due to cancer treatment in survivors of childhood cancer and the importance of lifelong monitoring for their development
  • Review hypothalamic pituitary disorders in childhood cancer survivors
  • Apply practical strategies to diagnosing thyroid disease in pediatric cancer patients and survivors
  • Discuss the challenges of obesity and diabetes mellitus in cancer survivors
Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.


Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC) - if eligible
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.50 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by The Endocrine Society and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Education Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. For questions about obtaining Nursing credit, please contact Sophia Kelley at skelley@clinicaloptions.com.

Continuing Pharmacy Education Credit Designation
CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-21-017-L01-P.

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

For questions about obtaining Pharmacy credit, please contact Sophia Kelley at skelley@clinicaloptions.com.

Faculty and Disclosures

Wassim Chemaitilly, MD - Program Chair
Associate Member, St. Jude Faculty
Director, Endocrinology Division
St. Jude Children’s Research Hospital
Memphis, TN

Laurie E. Cohen, MD
Director of the Neuroendocrinology Program
Director of the Growth Program 
Director of Clinical Innovation and Digital Health, Division of Endocrinology
Boston Children’s Hospital
Boston, MA

Danielle N. Friedman, MD, MS
Pediatric Long-Term Follow-Up Program
Department of Pediatrics
Memorial Sloan Kettering Cancer Center
New York, NY

Steven G. Waguespack, MD
Professor of Internal Medicine and Pediatrics 
University of Texas MD Anderson Cancer Center
Houston, TX

STATEMENT OF INDEPENDENCE
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.


The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Laurie E. Cohen, MD: Research Investigator, Pfizer, Inc.; Speaker, Novo Nordisk; Other, Sandoz
Danielle N. Friedman, MD, MS: Advisory Board Member, Fennec

The following faculty reported no relevant financial relationships during the content development process for this activity: Wassim Chemaitilly, MD; Steven G. Waguespack, MD

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:  Beret Anne Casey, MD

The following SPC Committee members reported financial relationships:

  • Andjela T. Drincic, MD: Advisory Board Member, Corcept
  • Sergio Fazio, MD, PhD: Consultant, Amarin, Amgen, Akcea, Aegerion, Esperion, Novartis
  • Angela M. Leung, MD: Speaker, Medical Education Resources, MCE Conferences, ATA Board Member
  • Amy Rothberg, MD: Spouse, consultant of Merck
  • Katherine Araque, MD: Speaker, Novo Nordisk; Advisory Board, Corcept

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:

Lorena Alarcon-Casas Wright, MD, Neena Natt, MD; Kelly Lauter Roszko, MD, PhD; Deborah Sellmeyer, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD

The staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.


ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Novo Nordisk, Inc.

Summary
Availability: On-Demand
Available Mar 26, 2021 to Mar 31, 2022
Cost: FREE
Credit Offered:
1.5 AMA PRA Category 1 Credits
1.5 ABIM-MOC Points
1.5 Participation Credits
1.5 ANCC Credits
1.5 ACPE Credits
Recommended
   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Powered By